KRAS
-
Official Full Name
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
-
Overview
GTPase KRas also known as V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog and KRAS, is a protein that in humans is encoded by the KRAS gene. Like other members of the Ras family, the KRAS protein is a GTPase and is an early player in many signal transduction pathways. KRAS is usually tethered to cell membranes because of the presence of an isoprenyl group on its C-terminus. The protein product of the normal KRAS gene performs an essential function in normal tissue signaling, and the mutation of a KRAS gene is an essential step in the development of many cancers. -
Synonyms
KRAS; v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; KRAS2, v Ki ras2 Kirsten rat sarcoma 2 viral oncogene homolog; GTPase KRas; KRAS1; K-Ras 2; c-Ki-ras; oncogene KRAS2; K-ras p21 protein; c-Kirsten-ras protein; PR310 c-K-ras oncogene; transformi;
- Recombinant Proteins
- Cell & Tissue Lysates
- Protein Pre-coupled Magnetic Beads
- Chicken
- Human
- Mouse
- Rhesus Macaque
- Zebrafish
- E. coli
- E.coli
- HEK293
- HEK293T
- Human Cell
- Human cells
- In Vitro Cell Free System
- Insect Cell
- Mammalian Cell
- Mammalian cells
- Sf9 insect cells
- Wheat Germ
- Avi
- biotinylated
- C
- His
- Myc
- DDK
- DYKDDDDK
- Flag
- GST
- His (Fc)
- His(N
- ter)
- MYC
- Myc|DDK
- N/A
- N
- No tag
- Involved Pathway
- Protein Function
- Interacting Protein
- KRAS Related Articles
- KRAS Related Research Area
- KRAS Related Signal Pathway
KRAS involved in several pathways and played different roles in them. We selected most pathways KRAS participated on our site, such as MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, which may be useful for your reference. Also, other proteins which involved in the same pathway with KRAS were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
| Pathway Name | Pathway Related Protein |
|---|---|
| MAPK signaling pathway | PRKACA;RRAS2;TNFRSF1A;GADD45BB;MAPK4;FGF2;MAP3K2;ZAK;PPP3CCA |
| ErbB signaling pathway | STAT5B;MAP2K4B;SHC4;PAK6B;PRKCA;AREG;PRKCB;PAK2B;GRB2 |
| Ras signaling pathway | FGF8;PLA2G6;PIK3R3;HRAS;FLT1;PLD2;RIN1;RASGRF2;PLA2G12B |
| Rap signaling pathway | PRKCB;PRKCZ;SKAP1;INS1;MAP2K1;PDGFA;CALML3;NRAS;PIK3R1 |
| Chemokine signaling pathway | CCL5;DOCK2;CXCR3;PRKCD;GNG10;CCL23;PPBP;GNG8;PAK1 |
| FoxO signaling pathway | IKBKB;PRKAB2;GRM1;GABARAPA;PIK3R1;NRAS;MAPK8;SOS1;PRMT1 |
| Sphingolipid signaling pathway | S1PR2;SGPP2;PIK3R1;SPHK1;GNAI1;LASS5;PLCB2;ROCK2;MAP3K5 |
| Phospholipase D signaling pathway | FYN;DGKE;INS2;PIK3CG;KIT;GRM5;AGTR1B;PRKCA;AVP |
| PIK-Akt signaling pathway | TCL1B4;PPP2CA;NGFR;YWHAB;GSK3B;RPTOR;EIF4E1B;FASLG;FGF18 |
| Dorso-ventral axis formation | ETS1;PIWIL2;EGFRA;CPEB1;MAPK1;SPIRE1A;NOTCH1;PPP1R2P9;GRB2A |
| Axon guidance | GNAI1;EPHB2;ROBO3;LAMTOR2;EPHB3A;SEMA7A;RHOC;SRGAP3;CDC42 |
| VEGF signaling pathway | VEGFAA;CDC42L2;PRKCA;PTGS2B;RAC3;RAC1B;PIK3CA;PLCG1;PLA2G4AA |
| Tight junction | PRKCH;JAM2;RAB3B;EPB41L2;NRAS;EXOC4;SMYHC1;PARD6GA;MYL2 |
| Gap junction | GNAI1;TUBA8L3;PRKACAB;GJD2;PRKG2;MAP2K2A;MAP2K1;DRD2B;TUBB1 |
| Signaling pathways regulating pluripotency of stem cells | WNT9B;WNT7A;NEUROG1;LEFTY2;APC;MAP2K2;PAX6;IGF1;ID3 |
| Natural killer cell mediated cytotoxicity | NFATC1;ARAF;SHC4;RAET1D;Fasl;LAT;KLRC4-KLRK1;PLCG2;HLA-E |
| T cell receptor signaling pathway | CD3E; CD3D;PPP3R1;MAPK9;NFKBIB;NFKBIA;SHB;MAPK3;CDC42;CD8B1 |
| B cell receptor signaling pathway | NFATC3;ARPC5;RASGRP3;ACTR2;LYN;CDK6;CD79B;RAP2A;GSK3AB |
| Fc epsilon RI signaling pathway | PRKCA;PDPK1;IL3;MS4A2;PLCG1;GRB2;LYN;PIK3R1;SYK |
| Long-term potentiation | GRM5;PLCB1;PPP1R1A;PPP1CB;EP300;NRAS;PPP3CC;PRKCB;PRKCG |
| Neurotrophin signaling pathway | HRAS;PIK3R3;MAPKAPK2;PIK3CB;NFKBIB;CAMK2B;CALM2;SH2B1;FOXO3 |
| Cholinergic synapse | CAMK2A;GNG12;PIK3R3;PLCB4;PIK3CG;FOS;FYN;CHRNA6;CAMK2G |
| Serotonergic synapse | HTR7;RAF1;ALOX12B;GNB3;ALOX15;GNG2;TPH2;PLA2G4D;HTR1B |
| Long-term depression | GRIA2;IGF1;RAF1;NRAS;GNAI1;ITPR1;GRID2;MAP2K2;PPP2R1A |
| Regulation of actin cytoskeleton | PTK2AB;ARHGEF7A;MAPK3;FGF20B;FGF1;MYL2B;SLC9A1;FGF12;RHOAA |
| Insulin signaling pathway | PRKACG;FLOT2A;G6PC2;ACACB;MAPK8A;KRAS;PKLR;AKT2L;GSK3B |
| GnRH signaling pathway | GNA11B;GRB2A;HBEGFA;PRKACB;GRB2B;PLA2G4F;PRKACAB;PRKACG;RAF1 |
| Progesterone-mediated oocyte maturation | CCNB1;PGR;ANAPC7;RPS6KA6;GNAI2B;PIK3R3A;PIK3R3B;ARAF;CCNA2 |
| Estrogen signaling pathway | SHC3;PIK3CG;SHC2;GABBR2;AKT2;CALML5;CALM3;AKT1;PIK3CD |
| Melanogenesis | WNT11;TCF7;CAMK2B1;CREB3L3;EDNRBA;WNT11R;HRASB;WNT6;MAP2K2 |
| Prolactin signaling pathway | FOS;SHC1;MAPK3;MAPK10;GRB2;RAF1;KRAS;NRAS;MAPK1 |
| Thyroid hormone signaling pathway | PIK3CD;SLC16A2;MED24;MDM2;ACTG1;PIK3R5;ATP1B3;STAT1;SIN3A |
| Oxytocin signaling pathway | MAPK3;CACNB3;ITPR1;PRKAG1;NFATC3;PRKAA1;RHOA;PRKAG2;GNAQ |
| Aldosterone-regulated sodium reabsorption | PRKCA;IGF1;ATP1A2;SLC9A3R2;MAPK3;KCNJ1;PRKCG;PIK3CD;IRS1 |
| Alcoholism | GM14483;HIST1H2BN;H2AFV;HRAS;HIST1H4J;GM14482;GRIN3A;CALM3;DDC |
| Hepatitis C | PPP2R2C;TYK2;PIK3CA;NFKB1;LDLR;IFNA10;RELA;IFNAR2;CLDN11 |
| Hepatitis B | IFNA13;HSPG2;MAPK3;MAPK10;TLR2;NFATC3;CCNE2;IRF7;IFNA16 |
| HTLV-I infection | PDGFRA;ELK1;EGR1;SPI1;CRTC1;PPP3CB;CD3E; CD3D;TSPO;ITGAL |
| Pathways in cancer | RET;FGF21;PLEKHG5;ARHGEF12;AKT1;EPAS1;BRAF;PRKCA;FGF5 |
| Viral carcinogenesis | SKP2;IL6ST;GTF2H2C;HDAC11;DDX3X;HIST1H2BH;PIK3CG;UBR4;HIST1H4N |
| Proteoglycans in cancer | GAB1;MMP2;MRAS;HPSE;STAT3;PLCG2;ITGA5;PRKCB;IL12B |
| MicroRNAs in cancer | PLAU;MDM4;NOTCH3;PLCG2;NOTCH4;KIF23;SIRT1;CCNG1;ITGB3 |
| Colorectal cancer | PIK3CG;PIK3R3;RHOA;RAF1;RALGDS;SMAD2;RAC3;MAPK10;TRP53 |
| Renal cell carcinoma | HRAS;PIK3CA;RBX1;PIK3CG;RAPGEF1;CUL2;RAF1;SLC2A1;RAC1 |
| Pancreatic cancer | AKT1;NFKB1;RAF1;RELA;RAC2;TGFB1;MAPK10;TGFA;PIK3R2 |
| Endometrial cancer | MAPK1;FOXO3;PIK3R2;CCND1;GRB2;APC2;TCF7;CTNNA3;KRAS |
| Glioma | SHC2;CAMK2G;CALM3;CAMK2D;MDM2;PLCG1;Pdgfa&Pdgfb;AKT1;PIK3CG |
| Prostate cancer | ACTL6B;SOS1;GSK3B;KRAS;CREB3L1;MAPK3;PIK3CA;GSTP1;TCF7L2 |
| Thyroid cancer | MAP2K1;PPARG;TPR;NRAS;CCDC6;PAX8;RXRA;RXRB;KRAS |
| Melanoma | FGF22;FGF10;FGF13;FGF6;FGF19;MDM2;FGFR1;PTEN;PDGFA |
| Bladder cancer | MMP9;CDK4;UPK3A;MDM2;MYC;KRAS;CDKN2A;MAPK1;MAP2K1 |
| Chronic myeloid leukemia | CCND1;RELA;CTBP1;TP53;PIK3R5;HDAC1;TRP53;SHC2;TGFBR2 |
| Acute myeloid leukemia | PIK3R3;ZBTB16;RPS6KB1;CCNA1;BAD;PIM1;RUNX1T1;MTOR;PIK3CG |
| Non-small cell lung cancer | KRAS;RXRB;MAP2K2;TRP53;GRB2;PIK3R2;PRKCA;RXRG;FOXO3 |
| Central carbon metabolism in cancer | PDHB;PFKP;RAF1;MAP2K1;PDK1;SLC1A5;SLC2A2;TP53;SLC2A1 |
| Choline metabolism in cancer | SOS1;AKT1;KRAS;MAPK9;WASF3;WASL;Pdgfa&Pdgfb;TAE1;WASF2 |
KRAS has several biochemical functions, for example, GDP binding, GMP binding, GTP binding. Some of the functions are cooperated with other proteins, some of the functions could acted by KRAS itself. We selected most functions KRAS had, and list some proteins which have the same functions with KRAS. You can find most of the proteins on our site.
| Function | Related Protein |
|---|---|
| GDP binding | RAB7;RRAS;PRPS2;EIF2B1;ARF1;PCK1;RAB17;IIGP1;SRP54B |
| GMP binding | RAB26;KRAS |
| GTP binding | DAPK1;ERCC3;RAP2A;EEF2A.1;DNM3A;LRRK1;RIT1;SEPT9;RAB27A |
| LRR domain binding | KRAS;ROBO1;ZXDC;STK11;LRRFIP2;POLR2J |
| protein binding | EREG;EXOC1;DEFB121;DGKQ;C10orf28;KCNA4;ARHGDIG;AMIGO2;GSTO1 |
| protein complex binding | INS2;RAD18;ULK1;PPARA;RBX1;RAN;ERCC6;VPS28;UFD1L |
KRAS has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with KRAS here. Most of them are supplied by our site. Hope this information will be useful for your research of KRAS.
ARAF; RASSF2; gtp; q46342_closo; Pik3ca; Rassf5; PIK3R2; RGL2; DEAF1; FRAT2; ZNF189; TNFSF13; DIRAS3; MOCS2; MT-CYB
Bettington, ML; Walker, NI; et al. A clinicopathological and molecular analysis of 200 traditional serrated adenomas. MODERN PATHOLOGY 28:414-427(2015).
Puzanov, I; Lindsay, CR; et al. A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors. CLINICAL CANCER RESEARCH 21:701-711(2015).
- Q&As
- Reviews
Ask a Question for All KRAS Products
Required fields are marked with *
My Review for All KRAS Products
Required fields are marked with *
